IP Library Granted Patent US 8,883,496
Granted Patent B2
US 8,883,496 · App. 13/113,677 · Granted Nov 11, 2014

Humanized FcgR mice

Inventors: Lynn MacDonald (White Plains, NY); Naxin Tu (Pleasantville, NY); Cagan Gurer (Valhalla, NY); Li-Hsien Wang (Somers, NY); Sean Stevens (San Francisco, CA); Andrew J. Murphy (Croton-on-Hudson, NY)
Assignee: Regeneron Phamaceuticals, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,883,496
App. No.
13/113,677
Granted
Nov 11, 2014
Kind
B2
Abstract

Genetically modified non-human animals and methods and compositions for making and using them are provided, wherein the genetic modification comprises a deletion of the endogenous low affinity FcγR locus, and wherein the mouse is capable of expressing a functional FcRγ-chain. Genetically modified mice are described, including mice that express low affinity human FcγR genes from the endogenous FcγR locus, and wherein the mice comprise a functional FcRγ-chain. Genetically modified mice that express up to five low affinity human FcγR genes on accessory cells of the host immune system are provided.

Claims (11)

1. An isolated mouse lymphocyte comprising a contiguous human nucleotide sequence that encodes at least two α-chains of an FcγR selected from FcγRIIA, FcγRIIB, FcγRIIC, FcγRIIIA, FcγRIIIB, and a combination thereof; wherein the contiguous human nucleotide sequence replaces mouse FcγR sequences in a mouse FcγR locus, and wherein the mouse lymphocyte comprises a functional FcR γ-chain gene.

2. The lymphocyte of claim 1 , wherein the at least two α-chains are human FcγRIIA α-chain and human FcγRIIIA α-chain.

3. The lymphocyte of claim 2 , wherein the human FcγRIIIA α-chain comprises a phenylalanine at amino acid position 158.

4. The lymphocyte of claim 2 , wherein the human FcγRIIIA α-chain comprises a valine at amino acid position 158.

5. The lymphocyte of claim 1 , wherein the at least two α-chains are selected from human FcγRIIB α-chain, human FcγRIIC α-chain, human FcγRIIIB α-chain, and a combination thereof.

6. The lymphocyte of claim 1 , wherein the lymphocyte is a B cell comprising a human nucleotide sequence that encodes a human CD20 protein, and wherein the lymphocyte does not express an endogenous mouse CD20 protein.

7. The lymphocyte of claim 1 , wherein the lymphocyte is an NK cell that expresses a human FcγRIIIA α-chain.

8. The lymphocyte of claim 1 , wherein the lymphocyte is a monocyte, a macrophage, a polymorphonuclear (PMN) cell, a basophil, an eosinophil, or a T cell, and wherein the lymphocyte expresses a human FcγRIIA α-chain.

9. The lymphocyte of claim 1 , wherein the lymphocyte is an NK cell.

10. The NK cell of claim 9 , wherein the NK cell expresses an α-chain of human FcγRIIC.

11. The NK cell of claim 9 , wherein the NK cell expresses an α-chain of human FcγRIIIA.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 6, 2011
From: MACDONALD, LYNN; TU, NAXIN; GURER, CAGAN; WANG, LI-HSIEN; STEVENS, SEAN; MURPHY, ANDREW J.
To: REGENERON PHARMACEUTICALS, INC.
Reel/Frame 026546/0979 →
Continuity (3)
Continuation In Part 12971080 · Dec 17, 2010
Provisional Application 61288562 · Dec 21, 2009
Related Publication 20110256556A1 · Oct 20, 2011